PMID- 17265020
OWN - NLM
STAT- MEDLINE
DCOM- 20070906
LR  - 20240426
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 56
IP  - 9
DP  - 2007 Sep
TI  - A new epitope peptide derived from hepatitis C virus 1b possessing the capacity 
      to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31, 
      and -A33.
PG  - 1359-66
AB  - BACKGROUND: Hepatitis C virus (HCV) frequently causes chronic hepatitis, 
      cirrhosis, and hepatocellular carcinoma after long-term persistent infection. 
      Among various genotypes of HCV, HCV1b is resistant to standard interferon 
      therapy, and thus the development of new treatment modality is needed. RESULTS: 
      To provide a scientific basis for specific immunotherapy for HCV1b, we 
      investigated HCV1b-derived epitope peptides recognized by human leukocyte antigen 
      (HLA)-A11, -A31, or -A33-restricted cytotoxic T-lymphocytes (CTLs), and report 
      here three novel vaccine candidate peptides selected by both antibody screening 
      and CTL-inducing capacity from among 46 peptides of conserved regions of HCV1b 
      sequences with binding motifs to HLA-A11, -A31, and -A33. Significant levels of 
      IgG reactive to each of the three peptides were detected in the plasma of more 
      than 50% of the HCV1b(+) patients. One peptide at positions 30-39 of the core 
      protein induced peptide-specific CTLs from peripheral blood mononuclear cells 
      (PBMCs) of HLA-A11(+), -A31(+), and -A33(+) patients. The other two peptides at 
      positions 35-43 of the core protein and at positions 918-926 of the 
      non-structural protein 2 also induced peptide-specific CTLs from the PBMCs of 
      HLA-A11(+) and -A33(+) patients. CONCLUSION: Therefore, the peptide at positions 
      30-39 of the core protein could be an appropriate target molecule of specific 
      immunotherapy for all HLA-A11(+), -A31(+), and -A33(+) patients with 
      HCV1b-related diseases.
FAU - Matsueda, Satoko
AU  - Matsueda S
AD  - Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, 
      830-0011, Japan.
FAU - Yamada, Akira
AU  - Yamada A
FAU - Takao, Yukari
AU  - Takao Y
FAU - Tamura, Mayumi
AU  - Tamura M
FAU - Komatsu, Nobukazu
AU  - Komatsu N
FAU - Yutani, Shigeru
AU  - Yutani S
FAU - Ide, Tatsuya
AU  - Ide T
FAU - Sata, Michio
AU  - Sata M
FAU - Itoh, Kyogo
AU  - Itoh K
LA  - eng
PT  - Journal Article
DEP - 20070131
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Epitopes)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A*33 antigen)
RN  - 0 (HLA-A11 Antigen)
RN  - 0 (HLA-A31 antigen)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Peptides)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amino Acid Sequence
MH  - Cell Line
MH  - Epitopes/chemistry/immunology
MH  - Female
MH  - HLA-A Antigens/chemistry/*immunology
MH  - HLA-A11 Antigen
MH  - Hepacivirus/*immunology
MH  - Hepatitis C/blood/*immunology
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Male
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Peptides/chemistry/immunology
MH  - T-Lymphocyte Subsets/cytology/*immunology
MH  - T-Lymphocytes, Cytotoxic/cytology/*immunology
PMC - PMC11029857
EDAT- 2007/02/01 09:00
MHDA- 2007/09/07 09:00
PMCR- 2007/01/31
CRDT- 2007/02/01 09:00
PHST- 2006/08/03 00:00 [received]
PHST- 2007/01/08 00:00 [accepted]
PHST- 2007/02/01 09:00 [pubmed]
PHST- 2007/09/07 09:00 [medline]
PHST- 2007/02/01 09:00 [entrez]
PHST- 2007/01/31 00:00 [pmc-release]
AID - 284 [pii]
AID - 10.1007/s00262-007-0284-5 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2007 Sep;56(9):1359-66. doi: 
      10.1007/s00262-007-0284-5. Epub 2007 Jan 31.